SEARCH:   Advanced

Blood, 1 June 2008, Vol. 111, No. 11, pp. 5291-5297. Prepublished online as a Blood First Edition Paper on March 11, 2008; DOI 10.1182/blood-2007-12-130120. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-12-130120v1 111/11/5291    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Ferrajoli, A. Articles by Keating, M. J. PubMed PubMed Citation Articles by Ferrajoli, A. Articles by Keating, M. J. Related Collections Neoplasia Free Research Articles Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia Alessandra Ferrajoli1, Bang-Ning Lee2, Ellen J. Schlette3, Susan M. O'Brien1, Hui Gao2, Sijin Wen4, William G. Wierda1, Zeev Estrov1, Stefan Faderl1, Evan N. Cohen2, Changping Li2, James M. Reuben2, and Michael J. Keating1 Departments of 1 Leukemia 2 Hematopathology Research 3 Hematopathology, and 4 Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston This study investigated the activity of lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Lenalidomide was given at 10 mg daily with dose escalation up to 25 mg daily. Three patients (7%) achieved a complete response (CR), one a nodular partial remission, and 10 patients a partial remission (PR), for an overall response (OR) rate of 32%. Treatment with lenalidomide was associated with an OR rate of 31% in patients with 11q or 17p deletion, of 24% in patients with unmutated VH, and of 25% in patients with fludarabine-refractory disease. The most common toxicity was myelosuppression, and the median daily dose of lenalidomide tolerated was 10 mg. Plasma levels of angiogenic factors, inflammatory cytokines, and cytokine receptors were measured at baseline, day 7, and day 28. There was a dramatic increase in median interleukin (IL)-6, IL-10, IL-2, and tumor necrosis factor receptor-1 levels on day 7, whereas no changes were observed in median vascular endothelial growth factor levels (20 patients studied). According to our experience, lenalidomide given as a continuous treatment has antitumor activity in heavily pretreated patients with CLL. This trial is registered at http://www.clinicaltrials.gov as no. NCT00267059 [ClinicalTrials.gov] . CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Lenalidomide: what is the right dose in CLL? Thomas S. Lin Blood 2008 111: 5268. [Full Text] [PDF] This article has been cited by other articles: Lenalidomide for Relapsed Chronic Lymphocytic Leukemia Patients Journal Watch Oncology and Hematology, July 8, 2008; 2008(708): 1 - 1. [Full Text]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020